Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avricore Health Inc V.AVCR

Alternate Symbol(s):  AVCRF

Avricore Health Inc. is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. The Company is involved in the business of health data and point-of-care technologies (POCT). HealthTab, its flagship offering, is a turnkey point-of-care testing solution that combines point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). The HealthTab also has capabilities for bacterial and viral tests, such as strep and COVID-19. The HealthTab platform transforms pharmacies into community point-of-care diagnostic centers.


TSXV:AVCR - Post by User

Bullboard Posts
Comment by goldeneggon Apr 03, 2015 5:12pm
135 Views
Post# 23595766

RE:nothing has changed with the company

RE:nothing has changed with the companyfeel better?

1.2b coming right up monday because that's how it works.



ROCKABERRYFIN wrote:

NPH Vanc Pharmaceuticals...

2 days ago CXR bought Covis for $1.2 Billion. Covis had 18 generic branded products

''The Covis drug portfolio being acquired consists of 18 branded and authorized generic products with stable revenue, strong margins and free cash flow. The distinctive product portfolio includes branded pharmaceuticals, injectables and authorized generics that address life threatening and other serious medical conditions in various therapeutic areas including cardiovascular, central nervous system, oncology and acute care markets.''
SOURCE


NPH has 49 products..(with 45 million shares out you do the math...)

CURRENT SATUS

Cross-referencing agreement – 30 products from globally reputed generic companies
Drug establishment license • Received in December 2014

Regulatory approval from Health Canada
• Submitted ANDS application for 33 productsand in process of submission for remaining products
• Received 67 DINs
• Remaining 16 Products to be filed in Q1-2015 with Health Canada
Vanc Pharmaceuticals Inc. has signed a letter of intent with a multichain pharmacy based in Western Canada to become a preferred supplier of generic drugs and over-the-counter products.
Vanc Pharmaceuticals Inc. has received confirmation from the B.C. Ministry of Health approving 14 of the company's generic molecules under the Low Cost Alternative program.
The approval of these molecules makes them eligible for listing on British Columbia's provincial formulary and for reimbursement through Pharmacare. Pharmacare is the province's coverage plan that assists residents with the cost of eligible prescription drugs and certain medical supplies.
"We are excited to have received LOA approval from the B.C. Ministry of Health as it signifies an important milestone in our evolution as a company -- we can now provide residents of B.C. with safety, quality and affordability when it comes to these 14 molecules," said Arun Nayyar, chief executive officer of Vanc. "We will continue to work with the Ministry of Health to gain approval of additional molecules during Q1 2015."
Next Steps
Ordering – Purchase orders placed for 30 products
Packaging and Artwork – Ready for 30 products and in process of gaining approvals from manufacturers Manufacturing
– Q1-2015 Provincial Listing
– Applied for all products Sales and Marketing
– Expand sales and marketing team Q2-2015
QC – testing method transfers are in progress and agreement in place with an Ontario based testing lab



Bullboard Posts